234 related articles for article (PubMed ID: 30203004)
1. Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells.
Davaadelger B; Murphy AR; Clare SE; Lee O; Khan SA; Kim JJ
Endocrinology; 2018 Oct; 159(10):3581-3595. PubMed ID: 30203004
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes.
Clare SE; Gupta A; Choi M; Ranjan M; Lee O; Wang J; Ivancic DZ; Kim JJ; Khan SA
BMC Cancer; 2016 May; 16():326. PubMed ID: 27215412
[TBL] [Abstract][Full Text] [Related]
3. Multiple human progesterone receptor messenger ribonucleic acids and their autoregulation by progestin agonists and antagonists in breast cancer cells.
Wei LL; Krett NL; Francis MD; Gordon DF; Wood WM; O'Malley BW; Horwitz KB
Mol Endocrinol; 1988 Jan; 2(1):62-72. PubMed ID: 3398843
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.
Knutson TP; Daniel AR; Fan D; Silverstein KA; Covington KR; Fuqua SA; Lange CA
Breast Cancer Res; 2012 Jun; 14(3):R95. PubMed ID: 22697792
[TBL] [Abstract][Full Text] [Related]
5. Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate.
Lee O; Sullivan ME; Xu Y; Rogers C; Muzzio M; Helenowski I; Shidfar A; Zeng Z; Singhal H; Jovanovic B; Hansen N; Bethke KP; Gann PH; Gradishar W; Kim JJ; Clare SE; Khan SA
Clin Cancer Res; 2020 Jan; 26(1):25-34. PubMed ID: 31570566
[TBL] [Abstract][Full Text] [Related]
6. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
8. New antiprogestins with partial agonist activity: potential selective progesterone receptor modulators (SPRMs) and probes for receptor- and coregulator-induced changes in progesterone receptor induction properties.
Giannoukos G; Szapary D; Smith CL; Meeker JE; Simons SS
Mol Endocrinol; 2001 Feb; 15(2):255-70. PubMed ID: 11158332
[TBL] [Abstract][Full Text] [Related]
9. TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.
Gizard F; Robillard R; Gross B; Barbier O; Révillion F; Peyrat JP; Torpier G; Hum DW; Staels B
Mol Cell Biol; 2006 Oct; 26(20):7632-44. PubMed ID: 17015480
[TBL] [Abstract][Full Text] [Related]
10. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.
Knutson TP; Truong TH; Ma S; Brady NJ; Sullivan ME; Raj G; Schwertfeger KL; Lange CA
J Hematol Oncol; 2017 Apr; 10(1):89. PubMed ID: 28412963
[TBL] [Abstract][Full Text] [Related]
11. Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).
Chen CC; Hardy DB; Mendelson CR
J Biol Chem; 2011 Dec; 286(50):43091-102. PubMed ID: 22020934
[TBL] [Abstract][Full Text] [Related]
12. Multimodal regulation of E2F1 gene expression by progestins.
Wade HE; Kobayashi S; Eaton ML; Jansen MS; Lobenhofer EK; Lupien M; Geistlinger TR; Zhu W; Nevins JR; Brown M; Otteson DC; McDonnell DP
Mol Cell Biol; 2010 Apr; 30(8):1866-77. PubMed ID: 20123965
[TBL] [Abstract][Full Text] [Related]
13. Progesterone agonists and antagonists induce down- and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines.
Savoldi G; Ferrari F; Ruggeri G; Sobek L; Albertini A; Di Lorenzo D
Int J Biol Markers; 1995; 10(1):47-54. PubMed ID: 7629427
[TBL] [Abstract][Full Text] [Related]
14. The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.
Ogara MF; Rodríguez-Seguí SA; Marini M; Nacht AS; Stortz M; Levi V; Presman DM; Vicent GP; Pecci A
Nucleic Acids Res; 2019 Nov; 47(20):10645-10661. PubMed ID: 31598691
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.
Faivre EJ; Daniel AR; Hillard CJ; Lange CA
Mol Endocrinol; 2008 Apr; 22(4):823-37. PubMed ID: 18202149
[TBL] [Abstract][Full Text] [Related]
16. Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
Lee O; Choi MR; Christov K; Ivancic D; Khan SA
Cancer Lett; 2016 Jul; 376(2):310-7. PubMed ID: 27080304
[TBL] [Abstract][Full Text] [Related]
17. Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression.
Esber N; Le Billan F; Resche-Rigon M; Loosfelt H; Lombès M; Chabbert-Buffet N
PLoS One; 2015; 10(10):e0140795. PubMed ID: 26474308
[TBL] [Abstract][Full Text] [Related]
18. The T47D cell line is an ideal experimental model to elucidate the progesterone-specific effects of a luminal A subtype of breast cancer.
Yu S; Kim T; Yoo KH; Kang K
Biochem Biophys Res Commun; 2017 May; 486(3):752-758. PubMed ID: 28342866
[TBL] [Abstract][Full Text] [Related]
19. Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system.
Afhüppe W; Sommer A; Müller J; Schwede W; Fuhrmann U; Möller C
J Steroid Biochem Mol Biol; 2009 Jan; 113(1-2):105-15. PubMed ID: 19130882
[TBL] [Abstract][Full Text] [Related]
20. Nuclear cathepsin D enhances TRPS1 transcriptional repressor function to regulate cell cycle progression and transformation in human breast cancer cells.
Bach AS; Derocq D; Laurent-Matha V; Montcourrier P; Sebti S; Orsetti B; Theillet C; Gongora C; Pattingre S; Ibing E; Roger P; Linares LK; Reinheckel T; Meurice G; Kaiser FJ; Gespach C; Liaudet-Coopman E
Oncotarget; 2015 Sep; 6(29):28084-103. PubMed ID: 26183398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
